Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance
Levesque S, Carleton G, Duque V, Goupil C, Fiset J-P, Villeneuve S, Normandeau E, Morin G, Dumont N, Nelson BH, Laganière J, Boyle B, Lum JJ, Doyon Y
bioRxiv 2023.09.14.557485 Article
Levesque S, Carleton G, Duque V, Goupil C, Fiset J-P, Villeneuve S, Normandeau E, Morin G, Dumont N, Nelson BH, Laganière J, Boyle B, Lum JJ, Doyon Y
bioRxiv 2023.09.14.557485 Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 211904 | MTOR-F2108L_CD19-CAR-28z-2A-EGFP_AAV6_Donor | Vector for AAV6 donor production. Targeted CD19-CAR-28z-2A-EGFP transgene integration to the MTOR locus with the dominant rapamycin resistance MTOR-F2108L mutation via homology-directed repair. |
| 211905 | MTOR-F2108L_DARIC(1)_CD19-scFv_AAV6_Donor | Vector for AAV6 donor production. Targeted CD19-scFv DARIC transgene integration to the MTOR locus with the dominant rapamycin resistance MTOR-F2108L mutation via homology-directed repair. |
| 211906 | TRAC_DARIC(2-3)_CD22-BBz_AAV6_Donor | Vector for AAV6 donor production. Targeted CD22-BBz DARIC transgene integration to the TRAC locus via homology-directed repair. |